Table 2.
Glycemic control of MiniMed 780G users over a 12-month period
| Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Users | 702 | 702 | 702 | 702 | 702 | 702 | 702 | 702 | 702 | 702 | 702 | 702 |
| SG, mg/dl | 142 ± 13.2 | 142 ± 13.2 | 142 ± 13.8 | 142 ± 14.0 | 143 ± 14.3 | 143 ± 14.7 | 143 ± 15.2 | 143 ± 15.0 | 143 ± 15.1 | 143 ± 15.8 | 144 ± 15.5 | 143 ± 14.7 |
| CV, % | 32.3 ± 4.7 | 32.3 ± 4.8 | 32.2 ± 4.7 | 32.1 ± 4.6 | 32.3 ± 4.8 | 32.3 ± 4.6 | 32.2 ± 4.7 | 32.2 ± 4.8 | 32.4 ± 4.8 | 32.3 ± 4.8 | 32.4 ± 4.8 | 32.4 ± 4.9 |
| GMI, % | 6.71 ± 0.32 | 6.71 ± 0.31 | 6.71 ± 0.33 | 6.71 ± 0.33 | 6.72 ± 0.34 | 6.72 ± 0.35 | 6.72 ± 0.36 | 6.73 ± 0.36 | 6.73 ± 0.36 | 6.74 ± 0.38 | 6.75 ± 0.37 | 6.74 ± 0.35 |
| TIR, % | 78.5 ± 8.4 | 78.5 ± 8.5 | 78.5 ± 8.9 | 78.4 ± 8.9 | 78.2 ± 9.1 | 78.2 ± 9.2 | 78.2 ± 9.3 | 78.1 ± 9.3 | 77.9 ± 9.3 | 77.8 ± 9.9 | 77.6 ± 9.6 | 77.7 ± 9.4 |
| TITR, % | 54.1 ± 10.4 | 54.2 ± 10.4 | 54.4 ± 10.7 | 54.2 ± 10.7 | 54.0 ± 10.8 | 54.1 ± 11.2 | 53.9 ± 11.1 | 53.6 ± 10.9 | 53.8 ± 11.0 | 53.6 ± 11.4 | 53.2 ± 11.2 | 53.4 ± 10.9 |
| TB70, % | 2.3 ± 2.1 | 2.3 ± 2.0 | 2.3 ± 2.0 | 2.3 ± 2.0 | 2.3 ± 2.0 | 2.3 ± 2.0 | 2.3 ± 2.0 | 2.2 ± 2.0 | 2.2 ± 1.9 | 2.2 ± 2.0 | 2.3 ± 2.1 | 2.3 ± 1.9 |
| TB54, % | 0.5 ± 0.7 | 0.5 ± 0.6 | 0.5 ± 0.6 | 0.5 ± 0.6 | 0.5 ± 0.6 | 0.5 ± 0.7 | 0.5 ± 0.7 | 0.4 ± 0.6 | 0.4 ± 0.6 | 0.4 ± 0.6 | 0.5 ± 0.6 | 0.5 ± 0.6 |
| % of users with GMI < 7%, TIR > 70% | 82.1 | 81.8 | 82.1 | 82.1 | 81.1 | 79.6 | 80.5 | 79.1 | 77.9 | 78.6 | 77.4 | 78.3 |
| % of users with GMI < 7%, TIR > 70%, TB70 < 4% | 67.2 | 67.9 | 68.8 | 67.1 | 67.1 | 65.8 | 68.5 | 67.5 | 65.7 | 63.5 | 63.2 | 63.8 |
| % of users with GMI < 7%, TIR > 70%, TB70 < 4%, TB54 < 1% | 66.5 | 66.1 | 66.7 | 65.7 | 66 | 64.2 | 67.5 | 66.1 | 64.8 | 63.1 | 61.5 | 62.3 |
| Median (IQR) sensor usage, days | 28.4 (26.4–29.1) | 28.2 (25.6–29.1) | 28.0 (25.5–29.0) | 28.2 (26.3–29.0) | 28.3 (26.3–29.1) | 28.2 (26.5–29.0) | 28.4 (26.8–29.1) | 28.4 (26.7–29.1) | 28.4 (26.8–29.0) | 28.3 (26.9–29.0) | 28.4 (27.0–29.1) | 28.2 (26.2–29.1) |
| Median (IQR) time on automatic mode, days | 28.9 (26.4–29.8) | 29.0 (26.1–29.8) | 28.7 (26.0–29.7) | 29.0 (26.9–29.8) | 29.1 (27.0–29.9) | 28.9 (27.3–29.8) | 29.0 (27.1–29.8) | 29.1 (27.2–29.9) | 29.1 (27.4–29.8) | 29.0 (27.5–29.8) | 29.1 (27.5–29.9) | 28.9 (26.8–29.8) |
| Basal % | 41.5 ± 8.5 | 41.0 ± 8.3 | 40.9 ± 8.3 | 40.7 ± 8.1 | 40.8 ± 8.1 | 40.9 ± 8.2 | 40.8 ± 8.0 | 40.8 ± 8.0 | 41.0 ± 8.4 | 41.2 ± 8.2 | 41.1 ± 8.2 | 40.9 ± 7.8 |
| Auto bolus % | 15.0 ± 6.5 | 15.6 ± 6.8 | 15.4 ± 6.9 | 15.7 ± 7.0 | 15.8 ± 7.2 | 15.7 ± 7.1 | 15.8 ± 7.1 | 16.0 ± 7.3 | 16.0 ± 7.1 | 16.2 ± 7.4 | 16.4 ± 7.3 | 16.5 ± 7.5 |
| TDD, U/day | 42.5 ± 23.5 | 43.5 ± 23.2 | 43.9 ± 23.4 | 44.6 ± 24.3 | 45.0 ± 24.7 | 45.1 ± 24.2 | 45.0 ± 23.3 | 45.2 ± 23.4 | 45.6 ± 23.5 | 46.0 ± 24.0 | 46.1 ± 23.7 | 46.7 ± 24.1 |
| ICR, g/U | 11.8 ± 5.9 | 11.6 ± 5.9 | 11.5 ± 5.7 | 11.4 ± 5.5 | 11.3 ± 5.5 | 11.3 ± 5.5 | 11.2 ± 5.5 | 11.2 ± 5.4 | 11.1 ± 5.3 | 11.1 ± 5.4 | 11.1 ± 5.3 | 11.0 ± 5.3 |
| Distinct ICRs, n/day | 1.81 ± 0.94 | 1.81 ± 0.95 | 1.84 ± 0.98 | 1.84 ± 0.98 | 1.86 ± 1.00 | 1.85 ± 0.98 | 1.85 ± 0.98 | 1.86 ± 0.99 | 1.88 ± 1.01 | 1.86 ± 1.00 | 1.87 ± 0.99 | 1.87 ± 0.99 |
All values are mean ± standard deviation unless otherwise indicated
CV, coefficient of variation; GMI, glucose management indicator; ICR, insulin-to-carbohydrate ratio; IQR, interquartile range; ROS, recommended optimal settings; SG, sensor glucose; TB54, time below 54 mg/dl; TB70, time below 70 mg/dl; TDD, total daily dose; TIR, time in range; TITR, time in tight range